Pavaki Capital Management’s Genmab GMAB Stock Holding History

Pavaki Capital Management’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$220K	Hold	8,000	–	–	0.08%	127
2026 Q1	$215K	Buy	+8,000	New	+$240K	0.09%	122

Other funds holding GMAB

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $10.6B AUM 19.39% 1-Year Est. Return

Pavaki Capital Management's GMAB Position: Q2 2026 in Review

Pavaki Capital Management held its Genmab (GMAB) position steady in Q2 2026 at 8,000 shares worth $220K. The position accounts for 0.08% of the portfolio, ranked #127.

Pavaki Capital Management first reported a position in GMAB in Q1 2026 and has held it in 2 quarters since. 276 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

Pavaki Capital Management held 8,000 shares of Genmab worth $220K as of Q2 2026.
Pavaki Capital Management left its Genmab share count unchanged in Q2 2026.
Genmab made up 0.08% of Pavaki Capital Management's portfolio in Q2 2026, its #127 holding.
Pavaki Capital Management first reported a position in Genmab in Q1 2026 and has held it in 2 quarters since.
276 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Pavaki Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.